GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Biovail Corporation (BVF) [hlAlert]

Rating:
Outperform
BVF
up 1,671.49 %

Biovail Corporation (BVF) upgraded to Outperform by Credit Suisse

Posted on: Monday,  Sep 14, 2009  8:25 AM ET by Credit Suisse

Credit Suisse rated Outperform Valeant Pharmaceuticals International Inc (NYSE: VRX) on 09/14/2009, when the stock price was $13.26.
Since then, Valeant Pharmaceuticals International Inc has gained 1671.49% as of 01/06/2016's recent price of $234.90.
If you would have followed this Credit Suisse's recommendation on VRX, you would have gained 1671.49% of your investment in 2305 days.

Biovail Corporation (Biovail) is a specialty pharmaceutical company that applies advanced drug-delivery technologies to improve the clinical effectiveness of medicines. The Company is engaged in the formulation, clinical testing, registration, manufacture and commercialization of pharmaceutical products. The Company has various research and development, clinical research, manufacturing and commercial operations located in Barbados, Canada, the United States and Puerto Rico. Its main therapeutic areas of focus are central nervous system (CNS) disorders, pain management and cardiovascular disease. The primary markets for its products are the United States and Canada. On September 16, 2008, Biovail acquired Prestwick Pharmaceuticals, Inc.

Excellence in equity and fixed income research is a hallmark of Credit Suisse. Globally, our equity research analysts provide in-depth coverage of over 2,500 companies and engage in a knowledge-sharing, value added culture that has yielded the most insightful product for our customers and tremendous competitive results. Additionally, Credit Suisse's powerful macro-economic and debt strategy teams integrate the bank's comprehensive company research with keen market perspectives of the ever-shifting investment terrain.
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy